Drugs in ATC Class V04CD

Up to Top Level ATC Classes

Up to V - Various

Up to V04 - DIAGNOSTIC AGENTS

Up to V04C - OTHER DIAGNOSTIC AGENTS

Drugs in ATC Class: V04CD - Tests for pituitary function

Tradename	Generic Name
GEREF	sermorelin acetate
MACRILEN	macimorelin acetate
METOPIRONE	metyrapone

V04CD Market Analysis and Financial Projection

The ATC Class V04CD encompasses diagnostic agents used for evaluating pituitary function, critical for diagnosing conditions like hypopituitarism and growth hormone deficiencies. This analysis explores the market dynamics and patent landscape for these diagnostic tools.

---

Market Dynamics

Growth Projections

• The global hypopituitarism diagnostics market was valued at $258.11 million in 2021, projected to reach $362.4 million by 2030 at a 5.8% CAGR [2].
• Alternative estimates suggest a larger market size, with $1.2 billion in 2024 growing to $2.5 billion by 2033 at a 9.1% CAGR [14].
• The combined pituitary hormone deficiencies market is expected to expand from $1.86 billion in 2022 to $2.71 billion by 2030, driven by genetic research and hormone replacement therapies [5][8].

Key Drivers

1. Rising Prevalence of Pituitary Disorders:
   • Over 4,000–10,000 people in North America have somatotropin deficiency [2].
   • Pituitary tumors, affecting 10,000+ annually in the U.S., are a major contributor [8].
2. Technological Innovations:
   • Advanced imaging (MRI), blood tests, and dynamic stimulation tests (e.g., insulin tolerance tests, GHRH-arginine tests) improve diagnostic accuracy [6][11].
   • Startups like Eli (Canada) are developing at-home hormone-monitoring devices [2].
3. Healthcare Investments:
   • Increased funding for endocrine disorder research and infrastructure upgrades [5][15].

Regional Insights

• North America dominates due to high disease prevalence and advanced healthcare systems [2][14].
• Asia-Pacific shows rapid growth, driven by rising awareness and healthcare access [14][15].

Emerging Trends

• AI and Machine Learning: Enhancing diagnostic accuracy and data analysis [8].
• Non-Invasive Diagnostics: Saliva and urine tests for cortisol monitoring gain traction [11][13].

---

Patent Landscape

Key Drugs and Agents

ATC Code	Drug	Use	Status
V04CD01	Metyrapone	Tests hypothalamic-pituitary ACTH function	Approved, generic available
V04CD06	Macimorelin	Diagnoses adult growth hormone deficiency	Newer oral agent, patented
V04CD	Corticorelin	Pituitary stimulation tests	Expired patents [10]

Innovations and R&D

• Macimorelin: A patented ghrelin mimetic offering oral administration advantages over injections [4][17].
• Proteomic Research: Mapping anterior/posterior pituitary proteins to improve diagnostic markers [9].

Regulatory and Clinical Trends

• Dynamic Testing Protocols: Emphasis on targeted stimulation tests (e.g., triple bolus tests) over combined panels [3][6].
• Guidelines: Expert endocrinologist oversight for interpreting results is critical [6][13].

---

Future Outlook

• Personalized Medicine: Genetic testing and biomarker identification will refine diagnostics [5][9].
• Patent Expiries: Expired patents (e.g., corticorelin) may increase generic competition, while newer agents like macimorelin drive innovation [4][10].

The ATC Class V04CD market is poised for steady growth, fueled by technological advancements and rising demand for precise endocrine diagnostics. Balancing patent expirations with novel drug development will shape competitive dynamics.

References

1. https://prediction.charite.de/subpages/tree.php
2. https://www.growthplusreports.com/report/hypopituitarism-diagnostics-market/8300
3. https://en.wikipedia.org/wiki/Combined_rapid_anterior_pituitary_evaluation_panel
4. https://go.drugbank.com/drugs/DB13074
5. https://www.databridgemarketresearch.com/reports/global-combined-pituitary-hormone-deficiencies-market
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC2905884/
7. https://publications.gc.ca/collections/collection_2016/cepmb-pmprb/RG79-1-1998-eng.pdf
8. https://www.thebusinessresearchcompany.com/report/combined-pituitary-hormone-deficiencies-global-market-report
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC9877467/
10. http://www.pmprb-cepmb.gc.ca/CMFiles/Publications/Annual%20Reports/2005_-_Patented_Medicines_-_Patentees38NXF-7122006-1017.pdf
11. https://www.ohsu.edu/brain-institute/pituitary-disorders-diagnosis-and-treatment
12. https://www.drugpatentwatch.com/p/atc-class/V04C
13. https://www.mayoclinic.org/diseases-conditions/hypopituitarism/diagnosis-treatment/drc-20351648
14. https://www.verifiedmarketreports.com/product/hypopituitarism-diagnostic-market/
15. https://www.futuremarketinsights.com/reports/hypopituitarism-diagnostics-market
16. https://go.drugbank.com/drugs/DB01011
17. https://pubchem.ncbi.nlm.nih.gov/compound/Macimorelin